Literature DB >> 22836557

Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?

Maria Cristina Da Mosto1, Valentina Lupato, Salvatore Romeo, Giacomo Spinato, Giancarlo Addonisio, Vittorio Baggio, Alessandro Gava, Paolo Boscolo-Rizzo.   

Abstract

BACKGROUND: The aim of the present study was to assess, in the setting of a single-institution prospective clinical trial, the necessity of planned neck dissection (PND) in physically and radiologically complete responders with pretherapy advanced nodal disease.
METHODS: Between January 2000 and July 2007 a total of 139 patients were enrolled to receive a regimen of platinum-based multidrug induction-concurrent chemoradiotherapy (IC/CCRT). A total of 75 of the enrolled patients with advanced nodal disease were included in this retrospective study. Between 8 and 12 weeks from the end of treatment, the response to IC/CCRT was evaluated by fiber-optic endoscopy and head and neck contrast-enhanced computed tomography or magnetic resonance imaging.
RESULTS: The complete clinical response (cCR) rate was 68%. Among the 51 patients who achieved locoregional cCR at the end of CCRT, 8 underwent PND according to the study recommendation. Of the 43 patients with cCR who did not undergo PND, 2 patients (4.7%) experienced isolated regional recurrences with the 5-year regional control being 82%. Patients with cCR did not have a significantly lower regional control compared with patients with cCR who underwent ND (P=.962). Pathological evidence of residual disease was found in 81% of the patients with less than cCR who underwent ND.
CONCLUSIONS: In physically and radiologically complete responders to IC/CCRT, a PND appears not justified. Conversely, PND should be performed in patients clinically suspected of having residual disease in the neck, as a significant proportion have viable tumor cell in post CCRT ND.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836557     DOI: 10.1245/s10434-012-2520-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

Authors:  R Montal; M Oliva; M Taberna; L De Avila; A Rovira; M Cos; M Mañós; V Navarro; J Nogués; A Lozano; L Rodríguez; E Vilajosana; S Vázquez; R Mesia
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

2.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

3.  Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long-term survival associated with human papilloma virus.

Authors:  Giacomo Spinato; Marco Stellin; Giuseppe Azzarello; Deborah Bonazza; Fabrizio Zanconati; Doriano Politi; Salvatore Cocuzza; Paola Di Mauro; Simonetta Ausoni; Giovanni Tonoli; Giulio Costantini; Luigi Maiolino; Roberto Spinato; Maria Cristina Da Mosto; Lorena Baboci; Annarosa Del Mistro; Agostino Serra; Giancarlo Tirelli
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

4.  Complete pathologic response as a prognostic factor for squamous cell carcinoma of the oropharynx post-chemoradiotherapy.

Authors:  Damila Cristina Trufelli; Leandro Luongo de Matos; Thaiana Aragão Santana; Fábio de Aquino Capelli; Jossi Ledo Kanda; Auro Del Giglio; Gilberto de Castro Junior
Journal:  Braz J Otorhinolaryngol       Date:  2015-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.